Toll Like Receptor 8 (CD288 or TLR8) – Pipeline Review, H2 2017

Global Markets Direct’s, ‘Toll Like Receptor 8 (CD288 or TLR8) – Pipeline Review, H2 2017’, provides in depth analysis on Toll Like Receptor 8 (CD288 or TLR8) targeted pipeline therapeutics. The report provides comprehensive information complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Toll Like Receptor 8 (CD288 or TLR8) targeted therapeutics development and features dormant and discontinued projects. The report analyses the pipeline products from therapy areas Oncology, Immunology, Infectious Disease, Dermatology, Gastrointestinal, Musculoskeletal Disorders and Respiratory under development targeting Toll Like Receptor 8 (CD288 or TLR8).

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

*Updated report will be delivered in 48 hours of order confirmation.

Scope

The report provides a snapshot of the global therapeutic landscape for Toll Like Receptor 8 (CD288 or TLR8)

The report reviews Toll Like Receptor 8 (CD288 or TLR8) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Toll Like Receptor 8 (CD288 or TLR8) targeted therapeutics and enlists all their major and minor projects

The report assesses Toll Like Receptor 8 (CD288 or TLR8) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Toll Like Receptor 8 (CD288 or TLR8) targeted therapeutics

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Toll Like Receptor 8 (CD288 or TLR8)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Toll Like Receptor 8 (CD288 or TLR8) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies mentioned

AstraZeneca Plc

Celgene Corp

Dynavax Technologies Corp

Eisai Co Ltd

Galderma SA

Gilead Sciences Inc

Idera Pharmaceuticals Inc

Janus Biotherapeutics Inc

MedImmune LLC

Nektar Therapeutics

Vivelix Pharmaceuticals Ltd

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 5

Introduction 6

Global Markets Direct Report Coverage 6

Toll Like Receptor 8 (CD288 or TLR8) - Overview 7

Toll Like Receptor 8 (CD288 or TLR8) - Therapeutics Development 8

Products under Development by Stage of Development 8

Products under Development by Therapy Area 9

Products under Development by Indication 10

Products under Development by Companies 12

Toll Like Receptor 8 (CD288 or TLR8) - Therapeutics Assessment 15

Assessment by Mechanism of Action 15

Assessment by Route of Administration 17

Assessment by Molecule Type 19

Toll Like Receptor 8 (CD288 or TLR8) - Companies Involved in Therapeutics Development 21

AstraZeneca Plc 21

Celgene Corp 21

Dynavax Technologies Corp 22

Eisai Co Ltd 22

Galderma SA 23

Gilead Sciences Inc 23

Idera Pharmaceuticals Inc 24

Janus Biotherapeutics Inc 24

MedImmune LLC 24

Nektar Therapeutics 25

Vivelix Pharmaceuticals Ltd 25

Toll Like Receptor 8 (CD288 or TLR8) - Drug Profiles 26

854-A - Drug Profile 26

Product Description 26

Mechanism Of Action 26

R&D Progress 26

durvalumab + MEDI-9197 - Drug Profile 27

Product Description 27

Mechanism Of Action 27

R&D Progress 27

DV-1001 - Drug Profile 28

Product Description 28

Mechanism Of Action 28

R&D Progress 28

E-6742 - Drug Profile 29

Product Description 29

Mechanism Of Action 29

R&D Progress 29

GS-9688 - Drug Profile 30

Product Description 30

Mechanism Of Action 30

R&D Progress 30

IMO-8400 - Drug Profile 31

Product Description 31

Mechanism Of Action 31

R&D Progress 31

IMO-9200 - Drug Profile 37

Product Description 37

Mechanism Of Action 37

R&D Progress 37

JB-6121 - Drug Profile 39

Product Description 39

Mechanism Of Action 39

R&D Progress 39

MEDI-9197 - Drug Profile 40

Product Description 40

Mechanism Of Action 40

R&D Progress 40

motolimod - Drug Profile 41

Product Description 41

Mechanism Of Action 41

R&D Progress 41

NKTR-262 - Drug Profile 45

Product Description 45

Mechanism Of Action 45

R&D Progress 45

resiquimod - Drug Profile 46

Product Description 46

Mechanism Of Action 46

R&D Progress 46

RSLV-132 - Drug Profile 48

Product Description 48

Mechanism Of Action 48

R&D Progress 48

VTX-1463 - Drug Profile 50

Product Description 50

Mechanism Of Action 50

R&D Progress 50

Toll Like Receptor 8 (CD288 or TLR8) - Dormant Products 51

Toll Like Receptor 8 (CD288 or TLR8) - Discontinued Products 53

Toll Like Receptor 8 (CD288 or TLR8) - Product Development Milestones 54

Featured News & Press Releases 54

Nov 07, 2017: Nektar to Present New On Drug Candidate NKTR-262 At 2017 Society for Immunotherapy of Cancer 32nd Annual Meeting 54

Aug 22, 2016: Resolve Therapeutics Announces Publication Of Clinical Data Demonstrating The Role Of Circulating RNA In Systemic Lupus Erythematosus 54

Jul 12, 2016: Mayo Clinic researchers identify potential immunotherapy drug combination 54

May 26, 2016: Resolve To Present Data On Lupus Studies At International Rheumatology Conference 55

Feb 10, 2016: Resolve Announces Positive Clinical Data From RSLV-132 Lupus Study 55

Dec 05, 2015: Idera Pharmaceuticals Reports Positive Data From Ongoing Phase 1/2 Clinical Trial of IMO-8400 in Patients With Waldenstrom’s Macroglobulinemia 56

Nov 09, 2015: Idera Pharmaceuticals Announces Initiation of Phase 2 Clinical Trial of IMO-8400 in Patients with Dermatomyositis 57

Nov 05, 2015: Idera Pharmaceuticals to Present Phase 1/2 IMO-8400 Clinical Data in Waldenstrom’s Macroglobulinemia at the 2015 American Society of Hematology Annual Meeting 58

May 18, 2015: Idera Pharmaceuticals Provides Development Update on IMO-9200, an Antagonist of Toll-like Receptors 58

Apr 27, 2015: VentiRx Pharmaceuticals Granted Orphan Drug Designation in the European Union For Motolimod in the Treatment of Ovarian Cancer 60

Apr 01, 2015: Idera Announces FDA Orphan Drug Designation for IMO-8400 for the Treatment of Diffuse Large B-Cell Lymphoma 60

Dec 30, 2014: Idera Provides Key Updates on Clinical Development of IMO-8400 for Treatment of Waldenstrom's Macroglobulinemia 61

Dec 08, 2014: Idera Pharmaceuticals Presents Data Supporting IMO-8400 as Novel Therapy for Genetically Defined Forms of B-Cell Lymphoma at Annual ASH Meeting 61

Nov 06, 2014: Idera Pharmaceuticals Announces Upcoming Presentations of Data on IMO-8400 From Oncology Programs at Key Scientific Meetings 63

Oct 14, 2014: Idera Pharmaceuticals Expands Pipeline by Initiating Clinical Development of Proprietary TLR Antagonist Candidate IMO-9200 63

Appendix 65

Methodology 65

Coverage 65

Secondary Research 65

Primary Research 65

Expert Panel Validation 65

Contact Us 65

Disclaimer 66

List of Tables

List of Tables

Number of Products under Development by Stage of Development, H2 2017 8

Number of Products under Development by Therapy Areas, H2 2017 9

Number of Products under Development by Indication, H2 2017 10

Number of Products under Development by Companies, H2 2017 12

Products under Development by Companies, H2 2017 13

Products under Development by Companies, H2 2017 (Contd..1), H2 2017 14

Number of Products by Stage and Mechanism of Actions, H2 2017 16

Number of Products by Stage and Route of Administration, H2 2017 18

Number of Products by Stage and Molecule Type, H2 2017 20

Pipeline by AstraZeneca Plc, H2 2017 21

Pipeline by Celgene Corp, H2 2017 22

Pipeline by Dynavax Technologies Corp, H2 2017 22

Pipeline by Eisai Co Ltd, H2 2017 23

Pipeline by Galderma SA, H2 2017 23

Pipeline by Gilead Sciences Inc, H2 2017 23

Pipeline by Idera Pharmaceuticals Inc, H2 2017 24

Pipeline by Janus Biotherapeutics Inc, H2 2017 24

Pipeline by MedImmune LLC, H2 2017 25

Pipeline by Nektar Therapeutics, H2 2017 25

Pipeline by Vivelix Pharmaceuticals Ltd, H2 2017 25

Dormant Products, H2 2017 51

Dormant Products, H2 2017 (Contd..1), H2 2017 52

Discontinued Products, H2 2017 53

List of Figures

List of Figures

Number of Products under Development by Stage of Development, H2 2017 8

Number of Products under Development by Therapy Areas, H2 2017 9

Number of Products under Development by Top 10 Indications, H2 2017 10

Number of Products by Mechanism of Actions, H2 2017 15

Number of Products by Stage and Mechanism of Actions, H2 2017 15

Number of Products by Routes of Administration, H2 2017 17

Number of Products by Stage and Routes of Administration, H2 2017 17

Number of Products by Molecule Types, H2 2017 19

Number of Products by Stage and Top 10 Molecule Types, H2 2017 19

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports